Protein C News and Research

RSS

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

1 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Routine blood test can reduce hospital readmissions in patients with heart failure

An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

'Tea and Toast Syndrome' leads to loss of wellness and muscle in seniors

Elderly people who live on their own that don't prepare whole meals or don't know how tend to dwindle their intake to "tea and toast" at the expense of vital nutrients and their health, according to an article published in the February issue of Food Nutrition & Science.

1 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Protein pathway may hold a clue for understanding Parkinson's disease

A protein pathway that may hold the secret to understanding Parkinson's disease has been discovered and explained by Iowa State University researchers.

1 Mar 2011

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

1 Mar 2011

Research uncovers new details about protein interactions in retina

Science fiction novelist and scholar Issac Asimov once said, "The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!' but 'That's funny.' " This recently rang true for an international team of researchers when they observed something they did not expect.

1 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Agilent Technologies acquires Lab901

Agilent Technologies Inc. today announced it has acquired Lab901, a leading electrophoresis equipment and consumables company based in Edinburgh, U.K. The company's automated electrophoresis products are used for DNA, RNA and protein analysis. Financial details of the acquisition were not disclosed.

28 Feb 2011

EPO grants three core patents to caprotec's CCMS technology

caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry technology.

28 Feb 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Researchers discover new mechanism of beta cell destruction not previously known

The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.

28 Feb 2011

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA, using Selcia's fragment screening technology. Novel and weak affinity hits were identified from Selcia's Fragment Library, using their proprietary CEfrag technique.

28 Feb 2011

New research may shed light on how HIV virus reactivates from latency

New research enhances the current knowledge of how human immunodeficiency virus type-1, which causes AIDS, controls the cell cycle of cells that it infects. The new findings may shed light on how the virus reactivates after entering a dormant state, called latency.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM Corporation and Merck, known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck.

28 Feb 2011

Protein C News and Research

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Routine blood test can reduce hospital readmissions in patients with heart failure

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

New personalized therapy fools cancer cells into killing themselves

'Tea and Toast Syndrome' leads to loss of wellness and muscle in seniors

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Protein pathway may hold a clue for understanding Parkinson's disease

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

Research uncovers new details about protein interactions in retina

PAH closely related to bone marrow abnormalities

Agilent Technologies acquires Lab901

EPO grants three core patents to caprotec's CCMS technology

p53 gene blocks EMT essential to cancer metastasis

Researchers discover new mechanism of beta cell destruction not previously known

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

New research may shed light on how HIV virus reactivates from latency

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

FUJIFILM enters definitive agreement to acquire Merck

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News